Target intelligence / Profile preview

Guanine nucleotide-binding protein G(s) subunit alpha and G protein subunit beta-gamma interface (Gαs/Gβγ interface)

Target
Gαs/Gβγ interface
Molecular classification
G protein, Heterotrimeric G protein complex, Signal transducer
01

Overview

The Gαs/Gβγ protein-protein interface is the structural junction between the alpha-s subunit (Gαs) and the beta-gamma (Gβγ) dimer within the heterotrimeric Gs protein complex. This interface is central to the canonical G protein signaling cycle, where GPCR activation triggers the exchange of GDP for GTP on Gαs, leading to the dissociation of the heterotrimer into Gαs-GTP and Gβγ subunits (UniProt P63092). The liberated Gαs-GTP then activates adenylate cyclase, increasing intracellular cAMP, while Gβγ can independently modulate various effectors like ion channels and kinases (StatPearls: G Protein-Coupled Receptors). Mutations in the Gαs subunit, such as those found in McCune-Albright syndrome or certain cancers, can lead to constitutive activation of this pathway (NIH/GARD). Therapeutic targeting of the Gαs/Gβγ interface aims to use small molecules or peptides to either stabilize the inactive heterotrimer or prevent the re-association/dissociation process, thereby modulating downstream signaling more selectively than broad GPCR ligands (PubMed: 16627734). While promising for treating G protein-related pathologies, the ubiquitous nature of Gs signaling poses significant risks for systemic toxicity and off-target effects.

Other names
GNAS/GNB/GNG interfaceGs heterotrimer interfaceG alpha s/G beta gamma complexGs protein-protein interface
02

Mechanism of action

Stabilization of the inactive heterotrimeric G protein complex or competitive inhibition of subunit dissociation to prevent effector activation.

03

Biological functions

Signal transductionAdenylate cyclase activationcAMP biosynthetic processG protein-coupled receptor signaling pathway
04

Disease associations

McCune-Albright syndromePituitary adenomaPseudohypoparathyroidismCancerCholera
05

Safety considerations

Broad systemic effects due to ubiquitous expressionPotential for endocrine disruptionCardiovascular side effectsOff-target GPCR signaling interference
06

Interacting drugs

Cholera toxin

4 more in the full profile.

07

Biomarkers

GNAS mutation statusIntracellular cAMP levelsAdenylate cyclase activity

Beyond the preview

Go deeper on Guanine nucleotide-binding protein G(s) subunit alpha and G protein subunit beta-gamma interface (Gαs/Gβγ interface).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guanine nucleotide-binding protein G(s) subunit alpha and G protein subunit beta-gamma interface (Gαs/Gβγ interface).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call